Boule Diagnostics

OverviewSuggest Edit

Boule Diagnostics, a diagnostics company, develops, manufactures, and distributes instruments and consumable products for hematology diagnostics for the public healthcare providers. It provides hematology analyzers, reagents, controls, and calibrators, as well as cleaning kits and plastic micro capillaries under the Swelab, Medonic, and Quintus brands; and veterinary hematology system under the Exigo brand. The Company serves hospitals, clinics, laboratories, and companies in blood diagnostics.

TypePublic
Founded1956
HQSpånga, SE
Websiteboule.com

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2021)218(+3%)
Revenue (FY, 2021)KR463.3 M(+16%)
Share Price (Jul 2022)KR26.7
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Boule Diagnostics

Peter von Ehrenheim

Peter von Ehrenheim

Chairman
Karin Dahllöf

Karin Dahllöf

Director
Christina Rubenhag

Christina Rubenhag

Acting CEO and Group President
Show more

Boule Diagnostics Office Locations

Boule Diagnostics has offices in Spånga, Plantation and Moskva
Spånga, SE (HQ)
4 Domnarvsgatan
Moskva, RU
4-Y Lesnoy Pereulok
Plantation, FL, US
1800 NW 65th Ave
Show all (3)

Boule Diagnostics Financials and Metrics

Boule Diagnostics Revenue

Embed Graph
View revenue for all periods
Boule Diagnostics's revenue was reported to be kr463.34 m in FY, 2021
SEK

Revenue (Q1, 2022)

132.5m

Gross profit (Q1, 2022)

64.5m

Gross profit margin (Q1, 2022), %

48.7%

Net income (Q1, 2022)

4.6m

EBITDA (Q1, 2022)

14.8m

EBIT (Q1, 2022)

10.3m

Market capitalization (27-Jul-2022)

518.4m

Closing stock price (27-Jul-2022)

26.7

Cash (31-Mar-2022)

36.2m

EV

656.4m
Boule Diagnostics's current market capitalization is kr518.4 m.
Annual
SEKFY, 2018FY, 2019FY, 2020FY, 2021

Revenue

424.4m498.9m400.5m463.3m

Cost of goods sold

(226.2m)(251.5m)(201.0m)(241.2m)

Gross profit

199.4m249.2m211.8m222.8m

Gross profit Margin, %

47%50%53%48%
Quarterly
SEKQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Revenue

118.6m119.7m131.2m118.4m90.6m98.8m100.6m110.7m111.8m132.5m

Cost of goods sold

(64.5m)(67.7m)(68.9m)(63.2m)(53.6m)(53.0m)(51.7m)(64.6m)(61.8m)(71.1m)

Gross profit

58.0m54.4m66.4m62.7m41.3m60.9m51.7m47.7m51.1m64.5m

Gross profit Margin, %

49%45%51%53%46%62%51%43%46%49%
Annual
SEKFY, 2018FY, 2019FY, 2020FY, 2021

Cash

30.3m21.6m33.0m38.2m

Accounts Receivable

110.9m127.4m93.6m127.9m

Prepaid Expenses

20.8m19.1m11.2m14.0m

Inventories

58.0m57.6m54.5m59.0m
Quarterly
SEKQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Cash

16.8m17.0m19.2m26.6m35.7m39.6m31.5m27.7m35.7m36.2m

Accounts Receivable

124.0m116.0m129.1m137.4m115.9m119.4m106.7m111.0m109.6m137.5m

Prepaid Expenses

20.8m25.9m29.6m20.1m11.8m17.3m23.3m22.1m20.7m9.6m

Inventories

62.1m58.6m61.4m65.2m69.6m55.7m51.1m58.9m57.9m69.4m
Annual
SEKFY, 2018FY, 2019FY, 2020FY, 2021

Net Income

54.8m70.0m(5.9m)36.0m

Depreciation and Amortization

8.4m21.4m21.6m21.5m

Inventories

(5.7m)1.3m(1.4m)(3.0m)
Quarterly
SEKQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Net Income

16.7m22.6m71.6m15.2m12.2m50.9m6.8m9.1m28.9m10.3m

Inventories

(3.4m)100.0k(5.0m)(6.1m)(11.9m)(4.7m)4.6m(3.5m)2.0m(11.2m)
SEKFY, 2018

Debt/Equity

0.3 x

Debt/Assets

0.2 x

Financial Leverage

1.7 x
Show all financial metrics

Boule Diagnostics Revenue Breakdown

Embed Graph

Boule Diagnostics revenue breakdown by business segment: 16.0% from INSTRUMENTS, 20.9% from CONSUMABLES OWN INSTRUMENTS, 9.1% from CONSUMABLES OEM AND CDS-BRAND, 50.0% from HEALTH CARE DIVERSIFIED and 3.9% from Other

Boule Diagnostics revenue breakdown by geographic segment: 100.0% from SWEDEN

Boule Diagnostics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

Boule Diagnostics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

30-39

out of 100

CSRHub logo

Boule Diagnostics Online and Social Media Presence

Embed Graph

Boule Diagnostics Blogs

Interim report Q3

The post Interim report Q3 appeared first on Boule.

Interpretation of a histogram – Veterinary focus

The post Interpretation of a histogram – <br>Veterinary focus appeared first on Boule.

Boule Diagnostics – Invitation to presentation of the interim report Q2 2022

The post Boule Diagnostics – Invitation to presentation of the interim report Q2 2022 appeared first on Boule.

Hematology needs – a clinicians perspective

The post Hematology needs – a clinicians perspective appeared first on Boule.

Interim report Q2

The post Interim report Q2 appeared first on Boule.

Bulletin from Annual General Meeting in Boule Diagnostics AB on May 5, 2022

The post Bulletin from Annual General Meeting in Boule Diagnostics AB on May 5, 2022 appeared first on Boule.
Show more

Boule Diagnostics Frequently Asked Questions

  • When was Boule Diagnostics founded?

    Boule Diagnostics was founded in 1956.

  • Who are Boule Diagnostics key executives?

    Boule Diagnostics's key executives are Peter von Ehrenheim, Karin Dahllöf and Christina Rubenhag.

  • How many employees does Boule Diagnostics have?

    Boule Diagnostics has 218 employees.

  • What is Boule Diagnostics revenue?

    Latest Boule Diagnostics annual revenue is kr463.3 m.

  • What is Boule Diagnostics revenue per employee?

    Latest Boule Diagnostics revenue per employee is kr2.1 m.

  • Who are Boule Diagnostics competitors?

    Competitors of Boule Diagnostics include Owlstone Medical, MasSpec Pen and Bactiguard.

  • Where is Boule Diagnostics headquarters?

    Boule Diagnostics headquarters is located at 4 Domnarvsgatan, Spånga.

  • Where are Boule Diagnostics offices?

    Boule Diagnostics has offices in Spånga, Plantation and Moskva.

  • How many offices does Boule Diagnostics have?

    Boule Diagnostics has 3 offices.